Phibro Animal Health (PAHC) Common Equity (2013 - 2026)

Phibro Animal Health's Common Equity history runs 14 years deep, the most recent figure standing at $361.8 million for Q1 2026.

• On a quarterly basis, Common Equity rose 36.03% year-over-year to $361.8 million in Q1 2026; TTM through Mar 2026 was $361.8 million, a 36.03% increase from a year earlier, with the FY2025 full-year figure at $285.7 million, up 11.32% from the prior year.
• Common Equity advanced to $361.8 million in Q1 2026 per PAHC's latest filing, from $332.4 million in the prior quarter.
• Across five years, Common Equity topped out at $361.8 million in Q1 2026 and bottomed at $246.8 million in Q4 2024.
• The 5-year median for Common Equity is $270.1 million (2024), against an average of $279.3 million.
• Across the five-year window, Common Equity fell 9.16% in 2024 and soared 36.03% in 2026, its largest moves.
• Year by year, Common Equity stood at $268.4 million in 2022, then climbed by 0.91% to $270.8 million in 2023, then retreated by 8.86% to $246.8 million in 2024, then soared by 34.67% to $332.4 million in 2025, then grew by 8.87% to $361.8 million in 2026.
• Per Business Quant, the three latest PAHC Common Equity figures stand at $361.8 million (Q1 2026), $332.4 million (Q4 2025), and $311.7 million (Q3 2025).